| Sun, Yongkun |
NCT05074966: The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts |
|
|
| Recruiting | 3 | 314 | RoW | Experimental: mXELOX plus cetuximab, Active Comparator: FOLFOX plus cetuximab | Chinese Academy of Medical Sciences | Colo-rectal Cancer | 06/24 | 06/25 | | |
NCT06403709: Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients |
|
|
| Active, not recruiting | 2 | 35 | RoW | Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab, Irinotecan+TAS-102+Bevacizumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Metastatic Colorectal Cancer | 08/24 | 08/26 | | |
NCT06543069: Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM |
|
|
| Recruiting | 2 | 28 | RoW | Sintilimab, Bevacizumab , Pemetrexed , Cisplatin, Sintilimab+Bevacizumab+Pemetrexed+ Cisplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Malignant Peritoneal Mesothelioma, Advanced | 01/26 | 01/27 | | |
NCT06345300: NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study |
|
|
| Recruiting | 2 | 40 | RoW | Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab, NALIRIFOX+PD-1, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate, NALIRIFOX | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu HengRui Medicine Co., Ltd. | Borderline Resectable Pancreatic Cancer | 12/24 | 12/25 | | |
NCT06490107: Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC |
|
|
| Active, not recruiting | 2 | 40 | RoW | Durvalumab combined with S-1, PD-L1+S-1 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, AstraZeneca | Biliary Tract Cancer | 12/26 | 12/27 | | |
NCT06202001: Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients |
|
|
| Recruiting | 1/2 | 70 | RoW | Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab, Irinotecan+TAS-102+Bevacizumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Metastatic Colorectal Cancer | 09/25 | 09/26 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
